Ouedraogo, 456 patient HCQ late treatment study: 33% lower mortality [p=0.38] and 68% lower severe cases [p=0.001] https://c19p.org/ouedraogo
copied to clipboard
Factors associated with the occurrence of acute respiratory distress and death in patients with COVID-19 in Burkina Faso
et al., Revue des Maladies Respiratoires, doi:10.1016/j.rmr.2021.02.001
Retrospective 456 patients in Burkina Faso showing lower risk of ARDS (p=0.001) and mortality (p=0.38) with HCQ.
|
risk of death, 33.0% lower, HR 0.67, p = 0.38, treatment 397, control 59, multivariate.
|
|
risk of ARDS, 68.0% lower, OR 0.32, p = 0.001, treatment 397, control 59, multivariate, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Ouedraogo et al., 2/5/2021, retrospective, Burkina Faso, Africa, peer-reviewed, 14 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.